Analyzing CAR-T Biodistribution with Digital PCR (dPCR)

Enhancing Preclinical Research Precision

In the dynamic landscape of gene and cell therapies (CGTs), the accurate understanding of cell product biodistribution is a pivotal component of monitoring safety and efficacy. This requirement can be met by the emergence of digital polymerase chain reaction (dPCR), a technology enabling precise quantification of DNA. The heightened sensitivity of dPCR over other technologies distinguishes target DNA from genomic background, which is crucial for efficient monitoring of biodistribution in animal models. Our presentation introduces a dPCR workflow tailored for assessing the biodistribution of human CAR-T therapy and leukemia cell lines in rodents. This innovative approach showcases our dPCR workflow's potential to optimize precision and reliability, setting a benchmark for preclinical assessment of investigational cell therapies.

I'm Interested In Attending

Save my seat once this webinar is published online.

More QIAGEN Events & Webinars

See other live webinars our partner, QIAGEN, is hosting to hear scientific talks, ask questions and exchange ideas with colleagues in your time zone.

Discover more

Built to Advance Your Noble Research

See what our clients say about working with Noble Life Sciences.

“Noble has been instrumental in enabling the accelerated testing of Jaguar’s preclinical gene therapy program. We are impressed by Noble’s experience and unparalleled support. As a leader in drug, device, and vaccine development, Noble appreciates the significance of Jaguar’s mission to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases.”

“Noble has been a strong partner for us, helping to accelerate testing of our synthetic biologics. Our Amicidins are new and innovative, requiring special attention to local application and performance in models. Noble has been flexible and agile in meeting our needs with high-quality work. We are pleased with the part Noble has played in advancing our programs, as we look to prevent and treat life-threatening infections in surgery and trauma.”

– Director, Preclinical Development

“The Noble team has done an outstanding job assisting us and accommodating our every need. Their guidance has been accurate, and their work has been excellent. They are experts in the field and are up-to-date with industry standards. We are grateful for everything they have done to help us advance the development of our regenerative medicine therapies.”

– CEO, Britecyte, Inc.

“We have been extremely impressed by Noble’s flexibility and dedication to quality. They have consistently gone above and beyond to meet our needs and have been a valuable partner in our growth. Their customer service is unmatched and we have enjoyed working with them on multiple projects. We are grateful for their partnership and look forward to continuing to work together in the future.”

– Co-Founder, DEKA BioSciences

“We needed a local CRO that is flexible and fast-paced to support our AAV gene therapy research and preclinical programs. Luckily, we found Noble who exceeded our expectations. Our teams work seamlessly as if they are an extension of our lab and provided necessary resources to advance our research in the most cost-effective way.”

– VP, Target Discovery & Early Portfolio